NGNE
Neurogene Inc.
$20.92
-$0.34(-1.60%)
35
Overall
60
Value
18
Tech
28
Quality
Market Cap
$305.77M
Volume
144.44K
52W Range
$6.88 - $37.27
Target Price
$59.00
Company Overview
| Mkt Cap | $305.77M | Price | $20.92 |
| Volume | 144.44K | Change | -1.60% |
| P/E Ratio | -4.1 | Open | $21.25 |
| Revenue | $925.0K | Prev Close | $21.26 |
| Net Income | $-75.1M | 52W Range | $6.88 - $37.27 |
| Div Yield | N/A | Target | $59.00 |
| Overall | 35 | Value | 60 |
| Quality | 28 | Technical | 18 |
No chart data available
About Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company is headquartered in New York, New York.
Latest News
Neurogene Inc. Reports Q3 2025 Financial Results
TipRanks Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NGNE | $20.92 | -1.6% | 144.44K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |